Reference health
Screening for osteoporosis after breast cancer: For whom, why and when
55/55 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
5 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 55 checked references that resolve
resolves10.1111/j.1365-2265.1992.tb01436.x
Assessment of the risk of post‐menopausal osteoporosis using clinical factors
resolves10.1001/jama.1996.03540170048031
Bone Mineral Density and Risk of Breast Cancer in Older Women
resolves10.1093/jnci/93.12.930
Bone Mass and Breast Cancer Risk in Older Women: Differences by Stage at Diagnosis
resolves10.1016/S0378-5122(00)00133-X
Association between breast cancer and bone mineral density: the Dubbo Osteoporosis Epidemiology Study
resolves10.1186/1471-2407-2-22
Bone mineral density and the subsequent risk of cancer in the NHANES I follow-up cohort
resolves10.1023/B:EJEP.0000036567.60387.39
Bone Mass Density and Risk of Breast Cancer and Survival in Older Women
resolves10.1016/S0140-6736(02)09088-8
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
resolves10.1056/NEJMoa052258
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
resolves10.1016/S1470-2045(07)70003-7
Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study
resolves10.1056/NEJMoa032312
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
resolves10.1056/NEJMoa040331
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
resolves10.1016/0021-9681(87)90061-0
Risk of osteoporotic fractures in women with breast cancer: A population-based cohort study
resolves10.1200/JCO.2007.15.7123
Tamoxifen Use and Osteoporotic Fracture Risk: A Population-Based Analysis
resolves10.1093/annonc/mdr356
High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy
resolves10.1016/S1470-2045(08)70204-3
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy
resolves10.1056/NEJM199809103391104
Endogenous Hormones and the Risk of Hip and Vertebral Fractures among Older Women
resolves10.1359/jbmr.2002.17.1.172
Role of Low Levels of Endogenous Estrogen in Regulation of Bone Resorption in Late Postmenopausal Women
resolves10.1093/annonc/mdi322
Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial
resolves10.1200/JCO.2005.05.4882
Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA.17
resolves10.1200/JCO.2005.07.097
Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer
resolves10.1016/j.berh.2009.09.003
Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer
resolves10.1038/bjc.1990.58
Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer
resolves10.1200/JCO.1997.15.4.1341
Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients.
resolves10.1007/s10549-005-3803-0
Changes on Bone Mineral Density after Adjuvant Treatment in Women with Non-metastatic Breast Cancer
resolves10.1200/JCO.2001.19.14.3306
Ovarian Failure After Adjuvant Chemotherapy Is Associated With Rapid Bone Loss in Women With Early-Stage Breast Cancer
resolves10.1093/jnci/djr242
Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis
resolves10.1359/jbmr.060508
Effect of an Aromatase Inhibitor on BMD and Bone Turnover Markers: 2-Year Results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230)
resolves10.1016/S0140-6736(04)17666-6
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
resolves10.1016/S1470-2045(07)70385-6
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
resolves10.1093/annonc/mdq541
Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial
resolves10.1016/S0140-6736(05)67059-6
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
resolves10.1093/annonc/mdl941
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial
resolves10.1093/annonc/mdp033
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
resolves10.1200/JCO.2004.08.148
Bone Mineral Density Among Premenopausal Women With Early Breast Cancer in a Randomized Trial of Adjuvant Endocrine Therapy
resolves10.1200/JCO.2005.02.3515
Tamoxifen Treatment After Adjuvant Chemotherapy Has Opposite Effects on Bone Mineral Density in Premenopausal Patients Depending on Menstrual Status
resolves10.1016/j.ejca.2006.07.005
Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study
resolves10.1200/JCO.2003.08.017
American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer
resolves10.1200/JCO.2009.26.3756
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
resolves10.1093/annonc/mdn164
Practical guidance for the management of aromatase inhibitor-associated bone loss
resolves10.1093/annonc/mdr017
Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment
resolves10.1016/j.ctrv.2008.03.007
Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group
resolves10.1007/s00198-011-1870-0
Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper
resolves10.1016/j.ejca.2011.10.021
The efficacy of zoledronic acid in breast cancer adjuvant therapy: A meta-analysis of randomised controlled trials
resolves10.1200/JCO.2008.16.3832
Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer
resolves10.1007/s10549-009-0352-y
Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study
The 5 references without a DOI — listed, not checked
no DOI — not checkedBone mineral density and endogenous hormones and risk of breast cancer in postmenopausal women (United States)
no DOI — not checkedAssociations between low levels of serum estradiol, bone density and fractures among elderly women: the Study of Osteoporotic fractures
no DOI — not checkedStructural analysis of the gene encoding human aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis
no DOI — not checkedRisk factors for a first-incident radiographic vertebral fracture in women>or =65 years of age: the study of osteoporotic fractures
no DOI — not checkedAdjuvant zoledronic acide in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/j.maturitas.2014.08.001"><img src="https://citestamp.com/citestamped/10.1016/j.maturitas.2014.08.001/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1016/j.maturitas.2014.08.001)